SCHEMBL26933019

SCHEMBL26933019

COc1ccc(C2CC2(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.53
▸ MAOA P21397 3/20 0.53
▸ KDM1A O60341 3/20 0.47
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ DDB1 Q16531 1/20 0.45
▸ CRBN Q96SW2 1/20 0.45
▸ RAB9A P51151 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ ACHE P22303 1/20 0.39
▸ NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13888944 0.81 MAOB (0.50) MAOBMAOAKDM1ACA12CA1
SCHEMBL12188964 0.81 MAOB (0.50) MAOBMAOAKDM1ACA12CA1
SCHEMBL11718044 0.80 MAOB (0.46) MAOBMAOAKDM1ACA12CA1
SCHEMBL27771288 0.79 MAOA (0.47) MAOBMAOAKDM1ACA12CA1
SCHEMBL4337820 0.79 MEN1 (0.63) MAOBMAOAKDM1ACA12CA1
SCHEMBL28118338 0.78 MAOB (0.45) MAOBMAOAKDM1ACA12CA1
SCHEMBL23994428 0.78 MAOA (0.43) MAOBMAOAKDM1ACA12CA1
SCHEMBL16885997 0.78 DDB1 (0.42) MAOBMAOAKDM1ADDB1CRBN
SCHEMBL16885912 0.77 MAOA (0.44) MAOBMAOAKDM1ADDB1CRBN
SCHEMBL27181178 0.76 ALDH1A1 (0.43) MAOBMAOAKDM1ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 — — US disclosed
CN-120004780-A Method for synthesizing polysubstituted pyrrole compound by taking difluoro cyclopropane as raw material 平顶山学院 2025-05-16 — — CN disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 — — US disclosed
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 — — EP disclosed
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2023-12-19 — — US disclosed
CN-117062804-A 1, 3-substituted cyclobutyl derivatives and their use 诺华股份有限公司 2023-11-14 — — CN disclosed
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2022-10-13 — — US disclosed
WO-2022201097-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2022-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 MAOB 1310/4885MAOA 2242/4885KDM1A 4513/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 MAOB 1310/4885MAOA 2242/4885KDM1A 4513/4885
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 MAOB 1310/4885MAOA 2242/4885KDM1A 4513/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 MAOB 1310/4885MAOA 2242/4885KDM1A 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback